CryoPort (NASDAQ:CYRX) Stock Rating Lowered by ValuEngine

CryoPort (NASDAQ:CYRX) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.

Several other analysts have also recently weighed in on CYRX. BidaskClub cut shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Wednesday, September 18th. Leerink Swann assumed coverage on shares of CryoPort in a research report on Monday, July 15th. They set a “buy” rating and a $24.00 price objective on the stock. Needham & Company LLC began coverage on shares of CryoPort in a research report on Monday, July 1st. They set a “buy” rating and a $22.00 price objective on the stock. B. Riley set a $26.00 target price on shares of CryoPort and gave the stock a “buy” rating in a research report on Friday, July 19th. Finally, Svb Leerink reiterated an “outperform” rating on shares of CryoPort in a research report on Monday, July 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $24.00.

Shares of CryoPort stock traded down $0.09 on Wednesday, hitting $14.83. 504,690 shares of the company traded hands, compared to its average volume of 687,626. The firm’s 50-day simple moving average is $19.69 and its 200 day simple moving average is $17.61. The company has a current ratio of 17.73, a quick ratio of 17.68 and a debt-to-equity ratio of 0.17. The company has a market cap of $531.04 million, a P/E ratio of -47.84 and a beta of 0.81. CryoPort has a 12-month low of $8.28 and a 12-month high of $25.02.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Thursday, August 8th. The consumer goods maker reported ($0.08) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). The firm had revenue of $8.46 million for the quarter, compared to analysts’ expectations of $7.94 million. CryoPort had a negative net margin of 35.71% and a negative return on equity of 17.32%. The business’s quarterly revenue was up 82.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.09) EPS. Analysts predict that CryoPort will post -0.3 earnings per share for the current year.

A number of large investors have recently modified their holdings of the stock. River & Mercantile Asset Management LLP purchased a new position in CryoPort in the 2nd quarter worth $3,326,000. Atria Investments LLC purchased a new position in CryoPort in the 2nd quarter worth $404,000. Royal Bank of Canada raised its position in CryoPort by 44.5% in the 2nd quarter. Royal Bank of Canada now owns 138,389 shares of the consumer goods maker’s stock worth $2,536,000 after purchasing an additional 42,623 shares during the period. Nuveen Asset Management LLC purchased a new position in CryoPort in the 2nd quarter worth $1,902,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in CryoPort in the 2nd quarter worth $12,830,000. Institutional investors own 59.59% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

See Also: QQQ ETF

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.